E-LIB Suche - Ergebnisse für: Hertzberg, M.

1

Toxicities at one year follow‐up in patients with advanced ..:

Ferdinandus, J. ; Moccia, A. A. ; Greil, R....
Hematological Oncology. 41 (2023) S2 - p. 363-364 , 2023

Link: https://doi.org/10.1002/..

2

Subgroup analysis of elderly patients (pts) with diffuse la..:

Hu, B. ; Reagan, P. M. ; Sehn, L. H....
Hematological Oncology. 41 (2023) S2 - p. 416-418 , 2023

Link: https://doi.org/10.1002/..

3

PHASE 1 STUDY OF JNJ‐67856633, A FIRST‐IN‐HUMAN MALT1 INHIB..:

Hertzberg, M. ; Kalac, M. ; Cheah, C. Y....
Hematological Oncology. 41 (2023) S2 - p. 131-132 , 2023

Link: https://doi.org/10.1002/..

4

BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANC..:

Borchmann, P. ; Moccia, A. A. ; Greil, R....
Hematological Oncology. 41 (2023) S2 - p. 881-882 , 2023

Link: https://doi.org/10.1002/..

5

Glofitamab plus R‐CHOP or polatuzumab vedotin‐R‐CHP is deli..:

Minson, A. ; Verner, E. ; Giri, P....
Hematological Oncology. 41 (2023) S2 - p. 421-422 , 2023

Link: https://doi.org/10.1002/..

6

S220: GLOFITAMAB INDUCES DURABLE COMPLETE REMISSIONS AND HA..:

Dickinson, M. ; Carlo-Stella, C. ; Morschhauser, F....
HemaSphere. 6 (2022) - p. 121-122 , 2022

Link: https://doi.org/10.1097/..

7

A PHASE III TRIAL OF GLOFITAMAB PLUS GEMCITABINE AND OXALIP..:

Hertzberg, M. ; Ku, M. ; Catalani, O....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

8

CLINICAL OUTCOMES FROM VENETOCLAX BASED THERAPY IN PATIENTS..:

Lewis, K.L. ; Dowling, M. ; Bavishi, K....
Hematological Oncology. 37 (2019) S2 - p. 535-537 , 2019

Link: https://doi.org/10.1002/..

9

Sustainable bioenergy for climate mitigation: developing dr..:

Taylor, G ; Donnison, I S ; Murphy-Bokern, D...
Annals of Botany. 124 (2019) 4 - p. 513-520 , 2019

Link: https://doi.org/10.1093/..

10

Oral health and dental morbidity in long‐term allogeneic bl..:

Dyer, G ; Brice, L ; Schifter, M...
Australian Dental Journal. 63 (2018) 3 - p. 312-319 , 2018

Link: https://doi.org/10.1111/..

11

PCN381 - REFERENCE VALUES FOR EORTC QLQ-C30 IN HODGKIN'S LY..:

Mierzynska, J. ; Taye, M. ; Pe, M....
Value in Health. 21 (2018) - p. S79 , 2018

Link: https://doi.org/10.1016/..

12

An individualised risk-adapted protocol of pre- and post tr..:

Grigg, A ; Butcher, B ; Khodr, B...
Bone Marrow Transplantation. 52 (2017) 9 - p. 1288-1293 , 2017

Link: https://doi.org/10.1038/..

13

IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIO..:

Hiddemann, W. ; Barbui, A.M. ; Canales Albendea, M.A....
Hematological Oncology. 35 (2017) S2 - p. 117-119 , 2017

Link: https://doi.org/10.1002/..

14

Second Cancer Risk and Late Mortality in Adult Australians ..:

Vajdic, Claire M. ; Mayson, Eleni ; Dodds, Anthony J....
Biology of Blood and Marrow Transplantation. 22 (2016) 5 - p. 949-956 , 2016

Link: https://doi.org/10.1016/..

15

Recent treatment advances in Hodgkin lymphoma: a concise re..:

Arulogun, S. ; Hertzberg, M. ; Gandhi, M. K.
Internal Medicine Journal. 46 (2016) 12 - p. 1364-1369 , 2016

Link: https://doi.org/10.1111/..